Is Theravance Biopharma, Inc. (TBPH) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 7.2% / 30% | 12.8% / 30% | 10.0% / 30% | 7.58% / 5% | ✗ NOT HALAL |
| DJIM | 7.2% / 33% | 12.8% / 33% | 10.0% / 33% | 7.58% / 5% | ✗ NOT HALAL |
| MSCI | 14.1% / 33% | 24.9% / 33% | 19.3% / 33% | 7.58% / 5% | ✗ NOT HALAL |
| S&P | 7.2% / 33% | 12.8% / 33% | 10.0% / 33% | 7.58% / 5% | ✗ NOT HALAL |
| FTSE | 14.1% / 33% | 24.9% / 33% | 19.3% / 50% | 7.58% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 65.2% | |
| Operating Margin | 43.6% | |
| Net Margin | 98.5% | |
| Return on Equity (ROE) | 44.8% | |
| Return on Assets (ROA) | -0.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$12M |
| Free Cash Flow | -$12M |
| Total Debt | $50M |
| Debt-to-Equity | 14.4 |
| Current Ratio | 10.9 |
| Total Assets | $354M |
Price & Trading
| Last Close | $15.19 |
| 50-Day MA | $17.51 |
| 200-Day MA | $15.29 |
| Avg Volume | 602K |
| Beta | 0.1 |
|
52-Week Range
$7.90
| |
About Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Theravance Biopharma, Inc. (TBPH) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Theravance Biopharma, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Theravance Biopharma, Inc.'s debt ratio?
Theravance Biopharma, Inc.'s debt ratio is 7.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 14.1%.
What are Theravance Biopharma, Inc.'s key financial metrics?
Theravance Biopharma, Inc. has a market capitalization of $777M, trailing P/E ratio of 7.3, and revenue of $64M. The company maintains a gross margin of 65.2% and a net margin of 98.5%. Return on equity stands at 44.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.